Community-Acquired Moraxella catarrhalis Bacteremic Pneumonia: Two Case Reports and Review of the Literature

نویسندگان

  • Miguel Angel Ariza-Prota
  • Ana Pando-Sandoval
  • Marta García-Clemente
  • David Fole-Vázquez
  • Pere Casan
چکیده

Moraxella (formerly Branhamella) catarrhalis was discovered at the end of the nineteenth century, and for many decades it was considered to be a harmless commensal of the upper respiratory tract. It is a Gram-negative, aerobic diplococcus considered to be the third most common pathogen isolated in childhood sinusitis and otitis media and in adult chronic lower respiratory disease, as well as an etiological agent of pneumonia in immunosuppressed patients or those with chronic obstructive pulmonary disease. Moraxella catarrhalis pneumonia is rarely associated with bacteremia. Here, we present two cases of community-acquired Moraxella catarrhalis bacteremic pneumonia.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Pneumonia caused by Moraxella catarrhalis in haematopoietic stem cell transplant patients. Report of two cases and review of the literature

Moraxella catarrhalis is a gram negative diplococcus that causes a variety of upper and lower respiratory tract infections. Patients with malignant, hematological disorders treated with intensive cytotoxic chemotherapy, and recipients of various forms of haematopoietic stem cell transplant receiving immunosuppressive agents are at high risk of developing severe infections and septic complicatio...

متن کامل

Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study

BACKGROUND Community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality throughout the world. Telithromycin (a new ketolide) has shown good in vitro activity against the key causative pathogens of CAP, including S pneumoniae resistant to penicillin and/or macrolides. METHODS The efficacy and safety of telithromycin 800 mg orally once daily for 7 days in the treatment of...

متن کامل

Ceftaroline: A Therapeutic Option for Community-Acquired Bacterial Pneumonia

On October 29, 2010, the U.S. FDA approved ceftaroline fosamil, a new cephalosporin with extended Gram positive coverage, for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia (CABP). Unlike the currently available cephalosporins, ceftaroline maintains bactericidal activity against multi-drug resistant Gram positive pathogens like MRS...

متن کامل

Moraxella catarrhalis - a rediscovered pathogen

Original Article Moraxella catarrhalis lower respiratory tract infection Beta Lactamase and Pneumonia

متن کامل

New antimicrobial agents approved by the U.S. Food and Drug Administration in 2004 and new indications for previously approved agents.

1 Apr 04 Ketek (tablets) Telithromycin Aventis For treatment of infections caused by susceptible strains of designated microorganisms for patients 18 yr old: acute bacterial exacerbations of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis; for acute bacterial sinusitis due to S. pneumoniae, H. influenzae, M. catarrhalis, or Staphylococcus ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 2016  شماره 

صفحات  -

تاریخ انتشار 2016